HIV-1 and immune control: can we change the course of HIV-1?
Kovacs
Andrea
A
Maternal, Child and Adolescent Center for Infectious Disease and Virology, University of Southern California Keck School of Medicine, Los Angeles, CA 90033, USA.
Connors
Mark
M
D019380:Anti-HIV Agents / Q000627:therapeutic use; D000943:Antigens, Differentiation / Q000276:immunology; D023241:Antiretroviral Therapy, Highly Active; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D015658:HIV Infections / Q000188:drug therapy / Q000276:immunology / Q000517:prevention & control*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D007156:Immunologic Memory / Q000276:immunology; D007167:Immunotherapy / Q000379:methods; D008213:Lymphocyte Activation / Q000276:immunology*; D016896:Treatment Outcome; D019562:Viral Load; D014766:Viremia / Q000276:immunology; D014779:Virus Replication / Q000276:immunology
D019380:Anti-HIV Agents; D000943:Antigens, Differentiation